ALB and idiopathic interstitial pneumonia: Consistent with these findings, a recent multicenter phase III clinical trial demonstrated that nintedanib combined with carboplatin plus albumin-bound paclitaxel effectively preserves lung function and may improve survival outcomes in NSCLC patients with IPF, particularly those with lower GAP scores (42).